They call it “Dr House’s diagnosis”, but it is real and invisible
There is a disease they call “Dr House’s diagnosis”, but it is real and “invisible”
There is a disease that is “invisible”, and for the public, society and often even the healthcare system, the people living with it can also become “invisible”. It is called sarcoidosis. Fans of the television series “Dr House” may remember that the famous doctor often used this mysterious name when trying to diagnose “unsolved cases”, although it was never the final diagnosis.
As many as ten percent of people may develop chronic sarcoidosis without knowing what the disease actually is. Initial findings often suggest lymphoma as a differential diagnosis, so patients may feel relief when they learn that the diagnosis is sarcoidosis. But the question remains: should sarcoidosis really be considered a “relief”?
UP TO 150 PEOPLE WITH SARCOIDOSIS
Dino-Josip Ključarić is one of the patients living with chronic sarcoidosis. He was born in Zagreb in 1981, is married, has five children and works as a manager in a security-systems company. Dino-Josip’s first symptoms of sarcoidosis appeared 20 years ago. The diagnosis was made only in August 2021. Since then, Dino-Josip has acquired above-average knowledge about his disease as a patient. One of the reasons is precisely his effort to reduce the “invisibility” of the disease, the difficulty of diagnosis and the uncertainty surrounding recovery.
“Sarcoidosis is an autoimmune multisystem disease. This means that the body’s own immune system attacks the organism from within, creating inflammatory processes that result from granulomas. Because the exact cause of the disease is unknown, and because it is assumed that these granulomatous processes may be triggered by unknown external influences, such as microbes, pesticides or air pollution, which initiate this immune response in people with a genetic predisposition, the disease itself and its treatment have not been fully researched. Therefore, there is no true cure; instead, medicine uses therapies to alleviate symptoms.
Some scientists say that sarcoidosis is not an autoimmune disease because the immune system does not attack itself, but rather an antigen that has entered the body. The consequence of this intense immune response to a foreign particle in the body manifests as an autoimmune disease because cytokines — which determine the intensity and duration of the immune response — continuously stimulate immune-inflammatory cells and directly or indirectly cause damage to target tissues. Sarcoidosis is therefore treated as an inflammatory granulomatous disease in which, due to an excessive immune reaction, all organs may be affected and destroyed,” says Dino-Josip.
We ask him how many people with sarcoidosis there are in Dalmatia, and how many there are in Croatia and worldwide.
“The number of patients is approximately four per 100,000 inhabitants. This would mean that, among 2.8 million Croatians, there are approximately 150 people diagnosed each year.”
Since 20 percent of Croatia’s population lives in Dalmatia, does this mean that the number of people with sarcoidosis in Dalmatia is approximately 30 per year?
“Unfortunately, we do not have an official exact number. I know that, among the 49 people who completed the sarcoidosis survey through our Facebook group, five were from Dalmatia: two cases each from Zadar and Split, and one from Dubrovnik. The question, however, is how many people even know that they have sarcoidosis, who has received a diagnosis and who is still classified as a ‘Dr House mystery case’.
Dalmatia is particularly dangerous for patients with sarcoidosis because the abundance of sunlight strongly stimulates the immune system, which is harmful in autoimmune diseases because it accelerates the disease. In addition, sunlight stimulates the production of vitamin D in our bodies, which acts as a catalyst for calcium. Calcium needs to be kept low in sarcoidosis because it is involved in granuloma formation.
Sarcoidosis can be acute and transient or chronic. Based on my own research, I arrive at a phenomenon in which two-thirds of patients are chronically ill — approximately 80 people in Croatia — although our association has fewer than 30 people with chronic sarcoidosis. In Europe and worldwide, especially among people with darker skin and those living in large cities, the incidence rises to as many as 15 patients per 100,000 inhabitants.
After the 11 September attack on the Twin Towers, the number of firefighters diagnosed with sarcoidosis was recorded, leading to the conclusion that, in addition to affecting people with darker skin and women more often, the disease may also be triggered by contact with toxic gases from major fires.”
When appearing before a disability-assessment commission, a person with sarcoidosis may have a good day and look healthy, yet collapse from weakness that same evening…
Sarcoidosis significantly reduces a person’s ability to live and work with a good quality of life.
JOINT PAIN
As a rare disease, what kind of “treatment” does sarcoidosis receive in Croatia?
Sarcoidosis significantly reduces a person’s ability to live and work with a good quality of life. The most common symptoms include joint pain, fatigue, insomnia, malaise and weakness, severe shortness of breath and skin irritation. In more severe cases, it can cause vision impairment, muscle weakness (myopathy), pulmonary hypertension and heart rhythm or function disorders. Although the disease is recorded as a single diagnosis under code D86, it contains many different diagnoses that systematically and simultaneously limit a person in everyday life. This is the paradox of the healthcare and pension systems, which often fail to recognise the severity and extent of the disease.
For example, the prescribed duration of sick leave for sarcoidosis is 30 days, while in 60 percent of patients the disease can cause incapacity for work lasting several months or longer during the year. Seasonal factors also affect fluctuations in the disease. Beautiful, sunny weather strengthens the immune system in most people, but in sarcoidosis this can mean increased pain and worsening health. Foggy and humid weather brings respiratory diseases, colds and viral infections, which represents a major challenge for people with sarcoidosis, who are highly immunocompromised, when trying to maintain even a minimum level of health. When appearing before a disability-assessment commission, a person with sarcoidosis may have a good day and look healthy, yet collapse from weakness that same evening…
Another problem is that sarcoidosis is not included on the list of diseases that cause disability; instead, it is assessed through similar descriptions. In pulmonary sarcoidosis, only the lung problems may be considered because the acute findings are in the lungs, while no one takes into account the multisystem attack, such as various inflammatory conditions including arthritis, or disabling conditions such as myopathy, chronic fatigue and malaise. It is well known that people with sarcoidosis may look healthy and flushed because of glucocorticosteroid treatment while internally they are “falling apart”. Social treatment, together with legal, social and healthcare protection, is often guided by this outward appearance and fails to consider the wider picture.
How are people with sarcoidosis treated in Croatia?
Most medicines used to treat sarcoidosis are prescribed for indications based on experience with other diseases because there is no targeted medicine for sarcoidosis. Establishing the diagnosis is the most difficult part. People with sarcoidosis may have symptoms resembling a heart attack or pulmonary embolism for years, yet leave the emergency department being told: “There is nothing wrong with you; you are young!” When an acute condition occurs, first-line treatment generally involves suppressing inflammation with corticosteroids. Synthetic glucocorticoids, such as Medrol, are used for their anti-inflammatory and immunosuppressive effects. Many people with sarcoidosis are resistant to corticosteroids or cannot tolerate them because of serious contraindications. In that case, cytostatic medicines such as methotrexate are added to the treatment. NSAIDs (non-steroidal anti-inflammatory drugs) may be used in combination with these medicines. Ultimately, if these medicines do not help or cause problems, biological medicines may be considered.
It is extremely important for every person with sarcoidosis to learn about diet and lifestyle adjustments. This information is not usually provided in hospital. It is important to avoid foods high in calcium, tap water because of its high calcium content, sunlight that stimulates vitamin D production and thereby acts as a catalyst for calcium, and immune-boosting preparations. A liver-friendly diet may be needed when taking high doses of corticosteroids, and so on. Fortunately, some patients enter spontaneous remission after the acute phase. Approximately two-thirds of them may enter remission without permanent damage, while around 10 percent will probably not avoid chronic problems. In general, the acute phase lasts one or two years; if the disease does not return within a year after remission, it probably will not return. In this respect, the best prognosis is associated with initial symptoms of Löfgren syndrome.
THEY CREATE IMMUNE CHAOS
Are there any new medicines or treatment methods in the world that could also be used in Croatia?
There are institutes around the world that conduct multidisciplinary research into the development and course of the disease. For example, through research into the activity of the TNF-alpha cytokine network, which is produced by macrophage activity and participates in granuloma formation, the United States has tried to regulate its production with pentoxifylline. So far, the results have been excellent. Pentoxifylline is not a medicine for sarcoidosis, just as our existing medicines are not, but it appears to be an excellent option because it does not cause the harmful effects on the body associated with corticosteroids. Padua is already conducting clinical trials of the immunomodulatory medicines infliximab and adalimumab. These medicines are already used in Croatia for some autoimmune diseases.
Sarilumab is also worth mentioning. It is a monoclonal antibody that binds to the cytokine IL-6 and thereby stops the “army of pro-inflammatory messengers” that create immune chaos. It is useful that it can be taken with methotrexate. In July 2019, a multicentre trial was launched to study sarilumab in patients with glucocorticoid-dependent sarcoidosis, and the second phase of the trial has recently been completed. In Croatia it is available under the name Kevzara, and it is approved by the hospital medicines committee based on the assessment of a specialist physician.
Can people with sarcoidosis in Croatia work, what problems do they face, and is there enough understanding from employers and society?
People with sarcoidosis have to work because their disease is usually not documented and assessed broadly enough. One of our fellow patients with sarcoidosis, who works in a bakery, has to stand next to blazing ovens and steam from 4 a.m. and complete her entire shift on her feet. Her paperwork lists pulmonary sarcoidosis, while the fact that she has severe ankle and knee pain somehow never became part of the medical documentation.
I am very fortunate and grateful to have an employer who has remarkable understanding of the disease, but I often feel guilty because the level of disability I was granted does not correspond to my actual level of disability for much of the year. I feel that society does not respond to what it does not understand, which is why spreading knowledge about sarcoidosis is one of the essential purposes of founding the Association of People with Sarcoidosis. People with sarcoidosis currently have an informal association within the Croatian Alliance for Rare Diseases. Its statutes are currently being voted on.
Since this is a rare disease, how much must patients educate themselves in order to manage their treatment as successfully as possible?
It is advisable for patients to follow support groups such as ours, which shares experiences and knowledge through the Facebook page “Sarcoidosis — the Snowflake Disease”, and to seek information on the website http://sarkoidoza.eu. It has proved useful that translated scientific articles and exchanges about medical practice among patients have already helped establish correct sub-diagnoses.
Sarcoidosis significantly reduces a person’s ability to live and work with a good quality of life.
IT IS ONLY MENTIONED IN MEDICAL SCHOOL
How up to date are Croatian doctors with sarcoidosis treatment methods used around the world? If a specific cure for sarcoidosis becomes available, would the Croatian Health Insurance Fund introduce it for patients in Croatia, given that their number is not large?
I assume that our doctors do not often have the opportunity to encounter all the faces of sarcoidosis. I believe they inform themselves from case to case, but they are not connected with one another when it comes to defining treatment and approaches to patients. A pulmonologist often will not see as deeply into the disease as a rheumatologist or cardiologist. They may meet when a patient is in an acute condition, and that is where the story begins and ends.
We are far from formalising experience and knowledge through an institutional consultation approach dedicated solely to sarcoidosis. It is most often treated by pulmonologists because pulmonary involvement is its most common form. Since the disease is multisystemic, neurologists, rheumatologists, cardiologists and other specialists also monitor it. People with sarcoidosis still do not receive the same treatment as patients with better-known diseases because sarcoidosis is rare. It can take two decades from the onset of the disease to the first diagnosis.
After diagnosis, treatment often depends on the time a doctor has available for a patient rather than on knowledge, because sarcoidosis is barely mentioned in medical school. We know that the healthcare system has a major shortage of doctors. This is a serious problem: a ward specialist may be responsible for 30 acutely ill patients in hospital beds and another 30–50 chronic patients attending a day hospital. How can one or two specialists provide quality care to someone with a rare disease with a hundred faces under such severe time constraints?
One of our fellow patients described the disease this way: Sarcoidosis has one name, but a hundred faces — just like snowflakes, which look the same from the outside but are completely different in structure.
What would patients like their families and the surrounding community to understand about sarcoidosis?
Sometimes our conversations about sarcoidosis focus too much on technical, tangible difficulties. I mean understanding the disease through symptoms, test results, treatments and side effects. Yet what makes us human is our psychological hygiene and strength of spirit. Mental strength is a person’s greatest and most abstract asset: you may lose everything, but you can get back up if you have preserved that strength.
It is reflected in cheerfulness, optimism, resourcefulness, independence and personal integrity. Unfortunately, illness can very quickly hit a person with absurd helplessness, loss of independence, the inability to maintain a smile or the rhythm of family and social life, and withdrawal in order to preserve strength because of pain. Sarcoidosis is not anyone’s fault; it arrives by chance.
Because sarcoidosis is not included in the register of diseases causing disability, and rights are assessed through comparisons and superficial knowledge, every person with sarcoidosis must make a great personal effort to find a way to cope with pain, the psychological burden described above and survival. I say all this in the hope that a more serious discussion will begin and create a strong voice that can be heard by those who can enable solutions through their signatures: a multidisciplinary approach to treatment, psychological support and counselling, social support, recognition of service-related benefits and recognition of disability,” concludes Dino-Josip Ključarić.
Dr Violeta Vučinić in Serbia
Are the methods used in other countries, for example Serbia, successful in treating sarcoidosis, and how does Croatia compare with those results?
Serbia has had the Serbian Sarcoidosis Association for many years. It was founded by Dr Violeta Vučinić, a pulmonologist internationally recognised for her work on sarcoidosis. Unfortunately, Serbia also uses conventional therapies that were approved by its ministry a long time ago. It is a matter of funding. A small number of patients represents a small problem and an insufficiently visible voice to move the system even slightly. In such cases, the principle of subsidiarity always fails.
A blow to the family
The disease confronts us with the loss of certain abilities, which is psychologically challenging because it means losing security, satisfaction, self-esteem, freedom, integrity and more. We should not forget how significant economic insecurity is in Croatia: people with disabilities may lose their jobs while trying to prove their disability, before they receive support, and the maximum support is lower than the minimum wage needed for a healthy person to survive.
This economic shock strikes at the stability and security of the family, not only financially and existentially, because it consequently causes anxiety within the family.
Dino-Josip Ključarić, MA in Theology
President of the Association of People with Sarcoidosis
Zagreb, 2023.
